<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0">

<channel>
<image>
<title>freepatentsonline.com</title>
<width>141</width>
<height>131</height>
<link>http://www.freepatentsonline.com/index.html</link>
<url>http://www.freepatentsonline.com/images/logo.gif</url>
</image>

<title>freepatentsonline.com: Drug, bio-affecting and body treating compositions</title>
<link>http://www.freepatentsonline.com/result.html?query_txt=ccl/424%20and%20isd/11/05/2009&amp;usapp=on</link>
<description>USPTO Class 424 Drug, bio-affecting and body treating compositions</description>
<language>en-us</language>
<lastBuildDate>Tue, 10 Nov 2009 08:53:34 EST</lastBuildDate>

<item>
<title><![CDATA[Drug delivery system based on cationic siloxanyl macromonomers]]></title>
<link>http://www.freepatentsonline.com/y2009/0274744.html</link>
<description><![CDATA[Matrix controlled diffusion drug delivery systems are described herein which are based on one or more silicon-containing monomers of the general formula:  
 wherein L, X − , n, R1, R2, R3, R4, R5, R6, R7 and V are as set forth herein.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Drug delivery systems based on catonic siloxanyl macromonomers]]></title>
<link>http://www.freepatentsonline.com/y2009/0274745.html</link>
<description><![CDATA[Matrix controlled diffusion drug delivery systems based on one or more silicon-containing monomers of the general formula:  
 wherein L, X − , n, R1, R2, R3, R4, R5, R6, R7 and V are as set forth herein.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Topical Application for Minimizing Melanin Production]]></title>
<link>http://www.freepatentsonline.com/y2009/0274749.html</link>
<description><![CDATA[Tyrosinase inhibitors are incorporated with liposomes in therapeutic compositions for topical application to hyperpigmentation. In particular, combinations of tyrosinase inhibitors are combined with liposomes to increase the penetration of the tyrosinase inhibitors into the deep epidermis skin layers and to provide hydration of the skin during treatment.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Therapeutic Treatment of Dermatologic Skin Disorders]]></title>
<link>http://www.freepatentsonline.com/y2009/0274750.html</link>
<description><![CDATA[Willowherb derivatives are incorporated with liposomes in therapeutic compositions for topical application to prevent or alleviate the conditions and symptoms of cosmetic and dermatologic disorders. In particular, willowherb derivates are combined with liposomes to increase the penetration of the willowherb derivates into the skin, to provide hydration of the skin during treatment.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[DUAL ACTION, INHALED FORMULATIONS PROVIDING BOTH AN IMMEDIATE AND SUSTAINED RELEASE PROFILE]]></title>
<link>http://www.freepatentsonline.com/y2009/0274754.html</link>
<description><![CDATA[Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Lithium combinations, and uses related thereto]]></title>
<link>http://www.freepatentsonline.com/y2009/0274775.html</link>
<description><![CDATA[The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT 2  receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor antagonist, a PDE4 inhibitor, an Neuropeptide Y5 Receptor Antagonists, a D4 receptor antagonist, a 5HT 1A  receptor antagonist, a 5HT 1D  receptor antagonist, a CRF antagonist, a monoamine oxidase inhibitor, a sedative-hypnotic drug, and an atypical antipsychotic.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Use in the cosmetics field of an extract of an exsudate of the plant daniellia oliveri, in particular as an antiwrinkle agent]]></title>
<link>http://www.freepatentsonline.com/y2009/0274779.html</link>
<description><![CDATA[The invention relates to the use, in a cosmetic composition or for the production of a cosmetic composition, of an extract of an exsudate of the plant  Daniellia oliveri,  said exsudate being at least partially made up of the oleoresin of said plant.  It relates most particularly to the use of this extract as a cosmetic agent for modifying the surface of the skin by giving it a smoother appearance through a reduction in the depth of the wrinkles and/or fine lines and/or by providing it with a re-plumping effect. It also relates to a cosmetic care method for modifying the surface of the skin by giving it a smoother appearance through a reduction in the depth of the wrinkles and fine lines and/or by providing it with a re-plumping effect, comprising the application, to the areas of the skin in question, of a cosmetic composition containing this extract.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[PLURIPOTENT THERAPEUTIC COMPOSITIONS AND USES THEREOF]]></title>
<link>http://www.freepatentsonline.com/y2009/0274660.html</link>
<description><![CDATA[Synthetic Stem Cell-like Tissue Healing and Regeneration Medication with Anti-inflammatory, Protein Synthesis, Enzyme Deficiency Activation and Genetic Therapy, and Anti-cancer Agent derived from a series of inventions that include these products of Biomolecular Engineering, Drug Discovery from a Biologic Periodic Table of Applied Biochemistry and Biophysics. Tissue has a self healing effect promoting tissue healing and tissue regeneration. Not only does it maintain good health but also it has been observed that the patient's blood is withdrawn from the patient and applied to the ulcer has healing qualities. Cartilage placed in a wound promotes and accelerates wound healing. The anabolic biochemical and biophysical equivalent of tissue has been found in these embodiments to have the same pharmacologic qualities, when devoid of genetic DNA mismatch and other catabolic factors including the catabolic effects of microorganism overgrowth that lacks pro-biotic qualities. The healing efficacy of these tissue components gives us further appreciation of the protective action of human tissue over and above and other than the immune protective system or perhaps an integral component part of the immune system.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[IMPLANTABLE DEVICES FOR PROMOTING REENDOTHELIALIZATION AND METHODS OF USE THEREOF]]></title>
<link>http://www.freepatentsonline.com/y2009/0274738.html</link>
<description><![CDATA[An implantable device for the controlled delivery of an estrogen receptor agonist to an injured site in the lumen of a mammalian blood vessel, wherein the estrogen receptor agonist is present in an amount of at least about 16.7 μg/mm implantable device length. Methods of use thereof.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Growth Factor Sensitive Vesicle]]></title>
<link>http://www.freepatentsonline.com/y2009/0274751.html</link>
<description><![CDATA[A generally spherical growth factor sensitive vesicle bearing growth factor receptors ( 12 ) having chemical compounds ( 14 ) covalently cross-linked to their non-growth factor binding domains. The chemical compounds are capable of associating to form larger chemical compounds ( 16 ) capable of destabilizing the vesicle. Methods for treating growth factor-overexpressing neoplasms are disclosed.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[IMMUNOADJUVANT]]></title>
<link>http://www.freepatentsonline.com/y2009/0274763.html</link>
<description><![CDATA[An immunoadjuvant comprising one kind or two or more kinds of immunostimulating substances carried separately by two or more kinds of different microparticle immunostimulating substance carriers, and comprising at least a combination of (a) an inorganic substance such as microparticle calcium phosphate having a size phagocytizable by cells, and (b) precipitates of a soluble protein and a mucopolysaccharide formed by coacervation as the microparticle immunostimulating substance carriers, which is highly safe and can exhibit potent immunoadjuvant activity.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Hollow Foam Beads for Treatment of Glioblastoma]]></title>
<link>http://www.freepatentsonline.com/y2009/0274764.html</link>
<description><![CDATA[Compositions and methods for the treatment of tumors are disclosed. Specifically, the present invention provides hollow foam beads having a chemotherapeutic agent incorporated therein. A method of making such beads is disclosed. In addition, a method for treating a glioblastoma tumor and other types of tumors with the compressible hollow foam beads is disclosed.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[PLANT PROTECTION GRANULATES TO BE APPLIED TO LEAF SURFACE]]></title>
<link>http://www.freepatentsonline.com/y2009/0274767.html</link>
<description><![CDATA[The present invention relates to granules for application to the leaf surface, and to a process for their preparation. The invention furthermore relates to the use of these granules for foliar penetration or the formulation of baits.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274771.html</link>
<description><![CDATA[Provided are compositions and methods for treating or preventing lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis (e.g. nose respiratory tract), and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein, the electrokinetically altered aqueous fluid suitable to alter cellular membrane structure or function sufficient to provide for modulation of intracellular signal transduction, wherein treating a lung disorder or a symptom thereof is thereby afforded. Additional aspects relate to therapeutic compositions, and combination treatment methods comprising administration of at least one electrokinetically generated fluid in combination with at least one additional therapeutic agent.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[DISINFECTANT COMPOSITIONS AND METHODS OF USE THEREOF]]></title>
<link>http://www.freepatentsonline.com/y2009/0274772.html</link>
<description><![CDATA[The present invention discloses a highly potent, non-toxic, disinfectant that can be used for a wide breadth of applications. The disinfectant comprises hydrogen peroxide (H 2 0 2 ), orange terpene oil, orange valencia oil, a non-ionic emulsifier (polysorbate 80), and water (H 2 0). Applications of the disinfectant include, but are not limited to, uses as a mouthwash, skin cleanser, or as a germicidal for disinfecting surfaces such as foodstuff, plant matter, leather, wood, metal, plastic and fabrics. Methods for using the disinfectant composition of the invention are also provided.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Citrate-Based Dialysate Chemical Formulations]]></title>
<link>http://www.freepatentsonline.com/y2009/0274774.html</link>
<description><![CDATA[The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Dietetic composition]]></title>
<link>http://www.freepatentsonline.com/y2009/0274777.html</link>
<description><![CDATA[(Problems) To provide a highly safe dietetic composition originating in green coffee beans by which excellent dietetic effects can be obtained and which contributes to the prevention and treatment of life style-related diseases such as diabetes.  (Means for Solving Problems) A dietetic composition characterized by comprising, as the active ingredient, a polar solvent extract of defatted green coffee beans. It is preferable that the above-described polar solvent extract is an extract obtained by using water-containing ethanol, still preferably water-containing ethanol having an ethanol concentration of from 40 to 90% (wt/wt). It is preferable that the above-described defatted green coffee beans are those obtained by extracting green coffee beans with N-hexane to thereby separate oily components therefrom. It is recommended to combine the above-described dietetic composition with one or more members selected from among salacia extract, evening primrose extract, sesamine and garcinia. This dietetic composition is usable as a material for foods, drinks, drugs, or skin preparations for external use.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[MENOPAUSE TREATMENT COMPOSITION AND REGIMEN]]></title>
<link>http://www.freepatentsonline.com/y2009/0274780.html</link>
<description><![CDATA[Disclosed are compositions and methods for treating symptoms associated with menopause and/or perimenopause. The compositions are based on a combination of concentrated extracts containing black cohosh, ginseng, red clover, soy isoflavones and St. John's wort, in the form of active compounds of these extracts. The treatment regimen, entail orally administering to a human subject suffering from symptoms of menopause and/or perimenopause, an effective dosage in effective amounts of the noted composition.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[ANTI-OBESITY AGENT]]></title>
<link>http://www.freepatentsonline.com/y2009/0274781.html</link>
<description><![CDATA[The present invention provides an anti-obesity agent having an anti-obesity effect obtained by combining a few extracts, which is attained by an anti-obesity agent containing Forsythia leaf extract, Citrus extract, and at least one extract selected from the group consisting of Licorice extract and Gardenia fruit extract, and it is preferable that the anti-obesity agent contains both Licorice extract and Gardenia fruit extract. The anti-obesity agent exhibits an ideal anti-obesity effect for increasing brown adipocytes and muscle weight to increase a basal metabolic rate and to decrease white adipocytes.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[ANTI-OBESITY AGENT]]></title>
<link>http://www.freepatentsonline.com/y2009/0274782.html</link>
<description><![CDATA[The present invention provides an anti-obesity agent having an anti-obesity effect obtained by combining a few extracts, which is attained by an anti-obesity agent (FC) containing Forsythia leaf extract and Citrus extract, and, in addition to these extracts, the anti-obesity agent containing Forsythia leaf extract, Citrus extract, and one extract selected from the group consisting of Licorice extract (FCGr) and Gardenia fruit extract (FCGf). These anti-obesity agents exhibited an ideal anti-obesity effect of decreasing white adipocytes while maintaining a basal metabolic rate without having a significant effect on brown adipocytes.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[HERBAL COMPOSITIONS AND METHODS FOR ENHANCING VITAL ENERGY AND ATHLETIC PERFORMANCE]]></title>
<link>http://www.freepatentsonline.com/y2009/0274783.html</link>
<description><![CDATA[Compositions, kits and methods are provided for enhancing vital energy and athletic performance, improving or restoring blood circulation, promoting mental acuity, reducing fatigue, and improving aerobic performance. In one embodiment, the composition comprises the herbal extracts of  Rhodiola crenulata  (root) and  Ginkgo biloba  (leaf). The composition can be used as a pharmaceutical or nutraceutical to promote mental concentration, and to promote aerobic and anaerobic performance by enhancing strength, endurance, muscle tissue oxygenation, and optimal oxygen consumption.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[PLANT EXTRACT MIXTURES AND THEIR USES]]></title>
<link>http://www.freepatentsonline.com/y2009/0274784.html</link>
<description><![CDATA[In one embodiment, a composition containing an effective amount of Cissus quadrangularis and one or more plants selected from the Brillantaisia and Vernonia plant families whereby the composition reduces the amount of fat absorbed or reduces weight in a mammal. Such compositions have beneficial activity principally in controlling weight gain and obesity, especially in conjunction with chitosan or a chitosan derivative and an antioxidant such as vitamin C.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[TOOTH POWDER CONTAINING ELVAN AS RADIATION SOURCE OF FAR INFRARED RAY]]></title>
<link>http://www.freepatentsonline.com/y2009/0274633.html</link>
<description><![CDATA[The present invention relates to tooth powder containing elvan as a radiation source of a far infrared ray wherein the tooth powder includes 10 weight % to 90 weight % of elvan as a radiation source of a far infrared ray and 10 weight % to 90 weight % of bamboo salt, and is characterized in that the rate of the elvan and the bamboo salt is 10:90 to 90:10. Also, it is of sovereign remedy in preventing teeth from decaying with medicine made by desiccating sap of a lacquer tree.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[TOOTH ENAMEL DISSOLUTION INHIBITOR]]></title>
<link>http://www.freepatentsonline.com/y2009/0274636.html</link>
<description><![CDATA[An object of the present invention is to provide a tooth enamel dissolution (decalcification) inhibitor that can inhibit the dissolution of tooth enamel to keep teeth healthy.  The tooth enamel dissolution inhibitor contains at least one member selected from the group consisting of guar gum, glucomannan, β-cyclodextrin, tragacanth gum, carrageenan, locust bean gum, hyaluronic acid, pullulan, pectin, and xanthan gum.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Ant Eradication Composition and Method]]></title>
<link>http://www.freepatentsonline.com/y2009/0274644.html</link>
<description><![CDATA[A composition and method for eradicating ants is provided wherein the composition includes borax, sugar and yeast. The messenger ants taste the composition; the workers take the composition back to the Queen who also eats the composition. The composition renders her infertile, and later distends the gastrointestinal tract.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[GALL MIDGE PHEROMONE MIXTURE]]></title>
<link>http://www.freepatentsonline.com/y2009/0274645.html</link>
<description><![CDATA[The present invention relates to a pheromone composition for attracting male Hessian fly,  Mayetiola destructor  (Say), for monitoring and/or combating purpose, said composition consisting of (2S,10E)-I-O-tridecen-2-yl acetate(2S-E10-13:OAc), (2S)-tridecan-2-yl acetate(2S-13:OAc), (2S,10E)-10-tridecen-2-ol (2S-E10-130H), and optionally (2S,8E,10E)-8,10-tridecadien-2-yl acetate(2S-E8-E10-13:OAc) and/or (2S,8Z,10E)-8,10-tridecadien-2-yl acetate(2S-Z8-E10-13:OAz), as well as a method for attracting said Hessian fly using such a composition.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Therapeutic Composition for the Treatment of BPH and ED]]></title>
<link>http://www.freepatentsonline.com/y2009/0274722.html</link>
<description><![CDATA[The invention relates to a therapeutic composition for the prevention and/or treatment of Benign Prostatic Hyperplasia (BPH) and other related prostate problems. The invention is a therapeutic composition that combines alfalfa and fennel to have a synergistic effect for the treatment of prostate problems, erectile dysfunction, and/or sleep disorders. The composition may further include ginger, red Reishi mushroom and oyster mushroom.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Bactericide having selectivity to cariogenic bacterium, and a method for sterilization of cariogenic bacterium]]></title>
<link>http://www.freepatentsonline.com/y2009/0274635.html</link>
<description><![CDATA[The bacteriolytic effect of a bacterial cell wall lytic enzyme can be increased by the addition of a surfactant to the enzyme. As a result, the time required for lysis of cariogenic bacterium with the bacterial cell wall lytic enzyme can be shortened, and the practical utility of the bacterial cell wall lytic enzyme (such as automutanolysin) as a prophylactic or therapeutic agent for dental caries can be improved.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Hair Care Compositions for Preventing Oxidative Damage to Hair, Methods of Use, and Methods of Marketing Such Compositions]]></title>
<link>http://www.freepatentsonline.com/y2009/0274642.html</link>
<description><![CDATA[Hair care compositions, methods, and methods of marketing that can prevent oxidative damage to hair. Such compositions comprise a follicular fungi reduction agent (“FFRA”) and can be applied to any areas where the appearance of less oxidative damage is desired, such as the scalp or face. The present invention also relates to methods of using and marketing such compositions.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Nutraceutical Compositions From Microalgae And Related Methods of Production And Administration]]></title>
<link>http://www.freepatentsonline.com/y2009/0274736.html</link>
<description><![CDATA[Provided herein are polysaccharide compositions and methods of culturing microalgae to produce polysaccharides. Also provided are methods of using polysaccharides for applications such as reducing cholesterol in mammals, inactivating viruses, stabilizing foods, and other uses. Also provided are transgenic algae capable of utilizing fixed carbon sources for energy. Also provided herein are novel nucleic acid sequences from red microalgae.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Stabilized composition]]></title>
<link>http://www.freepatentsonline.com/y2009/0274756.html</link>
<description><![CDATA[It is intended to provide a pharmaceutical composition which contains a proton pump inhibitor and is stable even if it is stored for a long time. It is also intended to provide a pharmaceutical composition which contains a proton pump inhibitor susceptible to acid, and does not dissolve in the stomach but dissolves in the intestine to release a primary drug product promptly. The object could be achieved by the pharmaceutical composition characterized in that a layer containing a proton pump inhibitor and ethyl cellulose, a layer containing an enteric polymer, and if necessary an intermediate layer composed of one or more layers are formed on a pharmacologically inactive core substance. The intermediate layer is composed of a water-insoluble polymer, a water-soluble polymer, a lubricant and the like.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Solid Composition for Intra-Oral Delivery of Insulin]]></title>
<link>http://www.freepatentsonline.com/y2009/0274758.html</link>
<description><![CDATA[The invention provides a solid composition for intra-oral delivery of insulin, comprising; insulin; a hydrophilic polymer matrix; and a phospholipid, providing insulin bioavailability of at least 5%.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[NECROSIS AVID TRACER AGENT]]></title>
<link>http://www.freepatentsonline.com/y2009/0274622.html</link>
<description><![CDATA[The invention relates to a method for obtaining an image of ischemic, infarcted or necrotic tissue in a subject, comprising the step of administering an imaging agent comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound. For example, the invention concerns to the use of phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives, and more specifically hypericin or its derivatives, as necrosis or infarct specific agents. The phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives can be labeled with a radionuclide, a radiopaque material or a material enhancing the effects magnetic resonance imaging. The invention further features a pharmaceutical composition comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound optionally conjugated to a radionuclide or a radiopaque material, provided that said phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound is not mono-[ 123 I]-iodohypericin.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Composition for Regeneration of Periodontal Soft Tissue and Method for Producing the Same]]></title>
<link>http://www.freepatentsonline.com/y2009/0274627.html</link>
<description><![CDATA[It is intended to provide a composition for regeneration of periodontal soft tissue less invasively and a method for producing the composition. The composition for regeneration of periodontal soft tissue is prepared so as to contain a cell selected from an undifferentiated/stem cell or a blast cell having an ability to form gingiva, a matrix material and blood platelet plasma. With the composition, free gingiva as well as attached gingiva can be regenerated less invasively with an effective and good aesthetics.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods for Controlling Molluscs]]></title>
<link>http://www.freepatentsonline.com/y2009/0274646.html</link>
<description><![CDATA[Novel materials for controlling molluscs, such as snails and slugs, using carbohydrates including celluloses, hemicellulose complexes, and/or lignin, for inducing death in molluscs. The materials are non-toxic, will not contaminate a drinking water supply, will not harm fish, birds or wild life, will not cause any harmful effects if swallowed or absorbed through the skin, will not harm children or pets, and can be safely eaten by domestic animals and livestock that may consume such dead molluscs. The materials may be applied in various formulations at various water contents. The materials do not provide nutrition to the molluscs, and disrupt normal bodily functions resulting in death. An attractant may be included to encourage ingestion by the molluscs.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen]]></title>
<link>http://www.freepatentsonline.com/y2009/0274697.html</link>
<description><![CDATA[This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-α (FR-α). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-α”), such as ovarian, breast, renal, colorectal, lung, endometrial, or brain cancer. The invention also relates to cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, and methods of detecting and treating cancer using the antibodies, derivatives, and fragments.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[COMPOSITIONS FOR COATING CELL MEMBRANES AND METHODS OF USE THEREOF]]></title>
<link>http://www.freepatentsonline.com/y2009/0274712.html</link>
<description><![CDATA[In certain aspects, the invention relates to cell delivery compositions comprising a progenitor cell and a targeting moiety, and methods related thereto. Such compositions and methods may be used, for example, in administering a targeted cell therapy cell therapy to a subject.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[TICK CHITINASE]]></title>
<link>http://www.freepatentsonline.com/y2009/0274715.html</link>
<description><![CDATA[A novel chitinase, a polynucleotide encoding the same, a vector and a transformant comprising the polynucleotide, an antibody against the chitinase, and a screening method for screening a substance capable of modifying the chitinase, are disclosed. According to the chitinase, polynucleotide, or vector, it is possible, for example, to exterminate ticks, or to treat or prevent tick-borne infections such as piroplasmosis, Q fever, or viral encephalitis.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[DRUG-LOADED MEDICAL DEVICES AND METHODS FOR MANUFACTURING DRUG-LOADED MEDICAL DEVICES]]></title>
<link>http://www.freepatentsonline.com/y2009/0274740.html</link>
<description><![CDATA[Drug-loaded medical devices such as stents and methods for manufacturing them are provided. In certain embodiments, the therapeutic agent is loaded only in or on areas of the medical device that do not undergo substantial deformation during expansion. The medical device may be provided with reservoirs in or on the first portions of the medical device that do not undergo substantial deformation during expansion, and the therapeutic agent may be loaded in these reservoirs. The reservoirs may be covered with a porous coating which may be a non-polymeric coating. In other embodiments, a non-polymeric coating is provided in a discontinuous manner in or on the medical device. A method includes the steps of providing a transfer member that includes a translucent substrate and a layer of transfer material such as a film or foil; attaching reservoirs to the transfer material; positioning the transfer member with the reservoirs adjacent a medical device, such as a stent, with the reservoirs facing the medical device; and directing a laser beam at the transfer member such that the laser beam passes through the translucent substrate to vaporize a portion of the transfer material, creating a pocket of trapped gas between the translucent substrate and reservoir, thereby forcing the reservoir from the transfer member to the medical device. The reservoirs may be formed of a non-polymeric material.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[COSMETIC USE OF A C-GLYCOSIDE DERIVATIVE IN COMBINATION WITH ASCORBIC ACID]]></title>
<link>http://www.freepatentsonline.com/y2009/0274638.html</link>
<description><![CDATA[The present invention relates to a cosmetic use of a synergistic combination of at least one C-glycoside derivative with at least ascorbic acid, or one of its derivatives or analogs, for preventively or curatively treating the signs of aging of body or facial skin, irrespective of whether they are chronobiological or photoinduced.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compositions and methods to treat urinary incontinence]]></title>
<link>http://www.freepatentsonline.com/y2009/0274678.html</link>
<description><![CDATA[A method is disclosed for treatment of urinary incontinence. The method includes the steps of providing to a person or animal, in the vicinity of a pubo-urethral ligament of the person or animal, a composition including collagen macromolecules that have hydroxyphenyl side groups substituted thereon, which are reacted to form dihydroxyphenyl linkages. In an embodiment, the collagen macromolecules are gelatin macromolecules. In another embodiment, the hydroxyphenyl side groups are tyramine side groups and the dihydroxyphenyl linkages are dityramine linkages. The composition can be injected into a space between a urethra and a pubis of the person or animal wherein the pubo-urethral ligament is disposed in the space. The method is advantageous, for example, based on being minimally invasive.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Co-Administration of a Thrombolytic and an Anti-CD18 Antibody in Stroke]]></title>
<link>http://www.freepatentsonline.com/y2009/0274689.html</link>
<description><![CDATA[A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Anti-staphylococcus aureus antibodies]]></title>
<link>http://www.freepatentsonline.com/y2009/0274704.html</link>
<description><![CDATA[A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody is enriched for immunoglobulins having both an antigen-binding portion that binds a  Staphylococcus aureus  capsular polysaccharide antigen and a constant region that does not bind staphylococcal protein A.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[LAGE-1 TUMOR ASSOCIATED NUCLEIC ACIDS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274716.html</link>
<description><![CDATA[The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compositions Comprising Hypsizygus Ulmarius Extract]]></title>
<link>http://www.freepatentsonline.com/y2009/0274721.html</link>
<description><![CDATA[Disclosed are topical compositions comprising extracts of  Hypsizygus ulmarius  in amounts that are effective to influence LTB4-mediated chemotaxis and/or IL-1β mediated adhesion of polymorphonuclear leukocytes. The  Hypsizygus ulmarius  extract may be used alone or in combination with secondary anti-inflammatory and skin active agents, such as other mushroom and/or natural extracts. The secondary anti-inflammatory agents may or may not function by antagonizing LTB4-mediated chemotaxis and IL-1β mediated adhesion. The extract may be incorporated into a cosmetically acceptable vehicle. The present invention includes methods of treating skin inflammation by applying to inflamed skin, anti-inflammatory effective amounts of  Hypsizygus ulmarius  extract in a defined treatment regimen.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Materials and Methods for Detecting, Preventing, and Treating Retroviral Infection]]></title>
<link>http://www.freepatentsonline.com/y2009/0274725.html</link>
<description><![CDATA[The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Type-2 Diabetes Combination Wafer]]></title>
<link>http://www.freepatentsonline.com/y2009/0274732.html</link>
<description><![CDATA[Rapidly disintegrating oral dosage forms for the application of active agent combinations for diabetes therapy. The dosage forms contain at least two active agents suitable for treating type-2 diabetes. The antidiabetic active agents are selected from the group comprising sulfonylureas, glitazones, glinides, biguanides, and absorption-delaying agents. The use of the active agent combination to produce an oral dosage form for the treatment of diabetes, a method for the therapeutic treatment of diabetes, and a method for the production of a sheet-like dosage form are also disclosed.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[METHODS AND COMPOSITIONS FOR TREATING NEOINTIMAL HYPERPLASIA]]></title>
<link>http://www.freepatentsonline.com/y2009/0274739.html</link>
<description><![CDATA[The present invention relates to compositions containing an mTOR inhibitor, such as rapamycin or a rapamycin derivative, in combination with a PI3 kinase inhibitor and/or a leptin inhibitor, intraluminal devices configured to release such compositions, and methods for the treatment and/or prevention of intimal hyperplasia, vascular stenosis and/or restenosis comprising delivery of such compositions or intraluminal devices to subjects in need thereof. The compositions, intraluminal devices, and methods of the invention are particularly well-suited for the treatment or prevention of vascular stenosis and restenosis in obese and diabetic subjects.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Pressure-Sensitive Adhesive Base and Medical Adhesive Patch Including the Pressure-Sensitive Adhesive Base]]></title>
<link>http://www.freepatentsonline.com/y2009/0274747.html</link>
<description><![CDATA[A pressure-sensitive adhesive base which contains the liquid organic ingredient and which, despite this, has moderate pressure-sensitive adhesion properties (tackiness and cohesive force) and causes no bleeding. It hardly injures the keratin of the skin and is inhibited from irritating the skin. The pressure-sensitive adhesive base comprises the following ingredients (A) to (C): (A) a copolymer comprising units of a monomer containing a carboxy group and units of a (meth) acrylic ester; (B) one or more, liquid or semisolid organic compounds which are compatible with the copolymer of the ingredient (A); and (C) at least one member selected among polyvalent-metal oxides and polyvalent-metal hydroxides, the total content of the ingredient (C) being 0.001-5 mass % based on the whole pressure-sensitive adhesive base. The adhesive base contains substantially no water.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Nonaqueous pressure-sensitive adhesive for medicinal tape preparation for percutaneous absorption, medicinal tape preparation for percutaneous absorption, and process for producing the same]]></title>
<link>http://www.freepatentsonline.com/y2009/0274748.html</link>
<description><![CDATA[A nonaqueous pressure-sensitive adhesive for a medicinal tape preparation for percutaneous absorption comprising (a) a support, (b) a pressure-sensitive adhesive layer containing a drug and a nonaqueous pressure-sensitive adhesive and (c) a release film laminated in that order, and a medicinal tape preparation for percutaneous absorption comprising the adhesive. The nonaqueous pressure-sensitive adhesive may comprise a copolymer obtained by copolymerization of a (meth)acrylic monomer having an acetoacetyl group in the molecule and one or more monomers from among other (meth)acrylic monomers without acetoacetyl groups and copolymerizable vinyl monomers, in a nonaqueous solvent. Suitable (meth)acrylic monomers having an acetoacetyl group in the molecule are acetoacetoxyalkyl methacrylates, and especially 2-acetoacetoxyethyl methacrylate. The copolymer nonaqueous pressure-sensitive adhesive of the invention, comprising a (meth)acrylic monomer having an acetoacetyl group as a constituent monomer, is capable of containing large amounts of lipophilic oily substances in the pressure-sensitive adhesive layer, and during heat drying, the acetoacetyl groups undergo self-crosslinking to form a network structure as the solvent evaporates off, so that large amounts of oily substances such as the plasticizer can be included in the network structure. The pressure-sensitive adhesive of the invention uses no polyamine derivatives, isocyanate compounds, polyvalent metal chelate compounds, etc., as crosslinking agents, and therefore toxicity is not a concern and skin is not irritated. A medicinal tape preparation for percutaneous absorption of the invention has superior adhesive strength and cohesive strength, and is highly safe with low skin irritation. It also has excellent drug release and percutaneous absorption properties.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[PH-SENSITIVE POLYMERIC MICELLES FOR DRUG DELIVERY]]></title>
<link>http://www.freepatentsonline.com/y2009/0274753.html</link>
<description><![CDATA[Mixed micelles containing poly(L-histidine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug in an acidic microenvironment, but not in the blood. Since the microenvironment of solid tumors is acidic, these mixed micelles are useful for treating cancer, including those cancers exhibiting multidrug resistance. Targeting ligands, such as folate, can also be attached to the mixed micelles for enhancing drug delivery into cells. Methods of treating a warm-blooded animal with such a drug are disclosed.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[SOLID PHARMACEUTICAL COMPOSITION WITH A FIRST FRACTION OF A DISPERSION MEDIUM AND A SECOND FRACTION OF A MATRIX, THE LATTER BEING AT LEAST PARTIALLY FIRST EXPOSED TO GASTROINTESTINAL FLUIDS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274759.html</link>
<description><![CDATA[A solid pharmaceutical composition in the form of a single dosage unit for oral use, the composition comprising a first and a second fraction, the first fraction comprises a therapeutically and/or prophylactically active substance dispersed in a dispersion medium that is sufficiently fluid at body temperature and the second fraction comprises a matrix comprising a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the first fraction being included in the composition in such a manner that at least a part of the second fraction is firstly exposed to the gastrointestinal fluids upon administration before the first fraction becomes exposed. The system is designed to release the active substance after a predetermined period of time after administration, and the release of the active substance at that point in time is relatively fast.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Use of An Alkyl Glycoside Or Of A Mixture Of Alkyl Glycosides Having Anti-Ageing And/Or Calming Properties As Active Agents In Cosmetic Compositions, And Methods Of Cosmetic Care Using Said Compositions]]></title>
<link>http://www.freepatentsonline.com/y2009/0274760.html</link>
<description><![CDATA[The present invention relates to a novel use of alkyl glycosides and of mixtures of alkyl glycosides having anti-ageing and/or calming properties as active agents in cosmetic compositions, and to methods of cosmetic care using the said compositions.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[TRANSDERMAL DELIVERY OF (R)-3,3-DIPHENYLPROPYLAMIN-MONOESTERN]]></title>
<link>http://www.freepatentsonline.com/y2009/0274761.html</link>
<description><![CDATA[The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C 1-4 alkyl, C 3-10 cycloalkyl, or phenyl, each of which can be substituted by C 1-3 alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compositions and Methods For Inhibiting Gastric Acide Secretion Using Derivatives of Small Dicarboxylic Acids in Combination with PPI]]></title>
<link>http://www.freepatentsonline.com/y2009/0274766.html</link>
<description><![CDATA[The present invention is related to novel oral compositions comprising an irreversible gastric H + /K + -ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more aliphatic carboxylic acid derivative molecules which activate parietal cells, wherein the derivatives possess delayed or sustained enhancement effect on the PPI activity compared to the non-derivatized acid molecules. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[HEALING COMPOSITION]]></title>
<link>http://www.freepatentsonline.com/y2009/0274769.html</link>
<description><![CDATA[The invention relates to a ternary composition characterized in that it consists of a source of carbohydrates, a source of divided minerals, chosen from clays, and a source of fatty acids. It also relates to a healing composition comprising said ternary composition. In said compositions, the source of carbohydrates is chosen from honeys and the source of fatty acids is chosen from oils rich in linoleic acid and linolenic acid.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[USE OF PYRENE TO CARRY NON-PEPTIDE AGENTS ACROSS THE BLOOD BRAIN BARRIER]]></title>
<link>http://www.freepatentsonline.com/y2009/0274621.html</link>
<description><![CDATA[Described are methods for delivering a non-peptide agent across the blood-brain barrier, comprising administering to a subject a conjugate comprising (i) a non-peptide agent and (ii) pyrene, and related detection and therapeutic method.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[IN VIVO IMAGING AGENTS FOR MET RECEPTOR TYROSINE KINASE]]></title>
<link>http://www.freepatentsonline.com/y2009/0274623.html</link>
<description><![CDATA[Provided are in vivo imaging agents comprising muteins of hTLc having detectable binding affinity for c-Met or a domain thereof, coupled to a signal generator, and the mutein coupled to a signal generator is disposed in a pharmaceutically acceptable carrier. Also provided are diagnostic methods using in vivo imaging agents comprising muteins of hTLc having detectable binding affinity for c-Met or a domain thereof.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[RECONSTITUTABLE MICROSPHERE COMPOSITIONS USEFUL AS ULTRASONIC CONTRAST AGENTS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274628.html</link>
<description><![CDATA[Methods and suspensions are provided that are useful for preparing readily reconstitutable, dry compositions of micro- or nanospheres. The dry compositions find use in diagnostic applications such as ultrasonic imaging. The suspension includes as key ingredients one or both of t-butyl alcohol and/or an amorphous sugar (or mixture of amorphous sugars) in specified amounts that reduce aggregation of the particles comprising the suspension.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Sanitizing Composition and Method of Preparation]]></title>
<link>http://www.freepatentsonline.com/y2009/0274629.html</link>
<description><![CDATA[The invention provides a sanitizing composition in the form of a viscous liquid or gel suitable for use as a handwash composition comprising alcohol, water and a thickener wherein the viscous liquid or gel has particles suspended therein, wherein said particles provide the composition with a granular texture and are capable of being worn away when rubbed. The particles may deliver one or more agents to the skin e.g. antimicrobial, antibacterial or antiviral agents, emollients and/or moisturizers, fragrances, colourings or UV markers.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions]]></title>
<link>http://www.freepatentsonline.com/y2009/0274631.html</link>
<description><![CDATA[RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[COMPOSITION FOR HAIR]]></title>
<link>http://www.freepatentsonline.com/y2009/0274639.html</link>
<description><![CDATA[It is an object of the present invention to provide a composition for hair which comprises a hydrophobic ingredient although it has an extremely low alcohol concentration, and which has a low viscosity. The present invention provides a composition for hair having a viscosity of 30 P or less, which comprises 1% to 50% by weight of alcohol and which further comprises a hydrophobic hair active ingredient.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Hair Care Compositions]]></title>
<link>http://www.freepatentsonline.com/y2009/0274640.html</link>
<description><![CDATA[Hair care compositions are disclosed which comprise a silicone polyurethane polymer, an ester, and a fluorosilicone. The compositions are useful for improving color retention of artificially colored hair.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[COSMETIC COMPOSITION COMPRISING ONE OR MORE VINYLFORMAMIDE/VINYLFORMAMINE COPOLYMERS AND ONE OR MORE THICKENING POLYMERS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274641.html</link>
<description><![CDATA[A cosmetic composition. In a cosmetically acceptable medium:
 
     one or more vinylformamide/vinylformamine copolymers, and one or more thickening polymers different from the vinylformamide/vinylformamine copolymers. 
     
  Can be used for hair styling, and can make it possible to obtain a particularly lasting retention of the hair style and hair conditioning properties.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Bispecific Antibody Point Mutations for Enhancing Rate of Clearance]]></title>
<link>http://www.freepatentsonline.com/y2009/0274649.html</link>
<description><![CDATA[A mutant bispecific antibody that includes (a) a human hinge constant region from IgG having one or more amino acid mutations in the C H 2 domain, (b) two scFvs; and (c) two Fvs has been constructed. This type of antibody displays enhanced clearance, which has been found to be particularly useful in the context of pre-targeting methods.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[INTERLEUKIN-2 MUTANTS WITH REDUCED TOXICITY]]></title>
<link>http://www.freepatentsonline.com/y2009/0274653.html</link>
<description><![CDATA[Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhancing peptide region of IL-2 achieve substantial reduction of vasopermeability activity as compared to a wildytpe form of the mutant IL-2 while retaining many of the immune activating properties of IL-2. Invention IL-2 mutants can be used to stimulate the immune system of an animal and may be used in the treatment of various disorders and conditions.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compositions And Methods For Producing Fermentation Products And Residuals]]></title>
<link>http://www.freepatentsonline.com/y2009/0274659.html</link>
<description><![CDATA[The present invention provides compositions and methods designed to increase value output of a fermentation reaction. In particular, the present invention provides a business method of increasing value output of a fermentation plant. The present invention also provides a modified fermentation residual of higher commercial value. Also provided in the present invention are complete animal feeds, nutritional supplements comprising the subject ferment residuals. Further provided by the present invention is a method of performing fermentation, a modified fermentative microorganism and a genetic vehicle for modifying such microoganism.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods And Kits For The Treatment Of Inflammatory Bowel Disorder Conditions]]></title>
<link>http://www.freepatentsonline.com/y2009/0274662.html</link>
<description><![CDATA[The present invention comprises methods and kits that are useful for the treatment an inflammatory bowel disease. The methods comprise administering to a mammal in need of treatment a composition comprising an active agent in combination with a probiotic and/or optionally an antibiotic.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[COMPOSITION FOR TOPICAL TREATMENT OF ACNE]]></title>
<link>http://www.freepatentsonline.com/y2009/0274673.html</link>
<description><![CDATA[The composition described is to be applied topically to the skin to treat acne and other skin disorders caused in part or wholly by bacterial or mycosal infections. Acne and related skin disorders have complex causes. This formula contains compounds, including an effective amount  Bacillus amyloliquefaciens  (Bam), that have distinct functions in reducing the sebum on the surface of the skin and inhibiting the proliferation of microbes and fungi where the skin has been wounded or in sebaceous pores. This formula also aims to increase the rate of healing of scars caused by acne by inhibiting opportunistic bacteria from colonizing the wound, while ensuring that healthier skin remains protected from such parasitic bacteria.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Migraine tonic]]></title>
<link>http://www.freepatentsonline.com/y2009/0274675.html</link>
<description><![CDATA[This invention is proposing a combination of a system of migraine headache remedies from non-prescription pharmaceuticals in the form of an aqueous drinkable tonic utilizing as the component foundation the main ingredient Ubiquinone (Co-enzyme-Q10) coupled with one or more of the following non-prescription natural or synthesized pharmaceuticals to include but are not inclusive of Tanacetum Parthenium, or Hypericin and/or Hyperforin, Petasin, Magnesium Citrate, and Riboflavin, the selection of which is determined upon the user and the user's other medications.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[ADAMTS13 GENES AND PROTEINS AND VARIANTS, AND THERAPEUTIC COMPOSITIONS AND METHODS OF UTILIZING THE SAME]]></title>
<link>http://www.freepatentsonline.com/y2009/0274683.html</link>
<description><![CDATA[The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[ILT3 POLYPEPTIDES AND USES THEREOF]]></title>
<link>http://www.freepatentsonline.com/y2009/0274685.html</link>
<description><![CDATA[This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system]]></title>
<link>http://www.freepatentsonline.com/y2009/0274690.html</link>
<description><![CDATA[Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca −−  signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in diagnostic and therapeutic applications, including screening assays for the discovery of additional antibodies that bind to cells of the nervous system, particularly oligodendrocytes.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Use of CD25 binding molecules in steroid-resistant patients]]></title>
<link>http://www.freepatentsonline.com/y2009/0274691.html</link>
<description><![CDATA[A method is provided for treating the diseases autoimmune hepatitis, eczema, vasculitis, temporal arteritis, sarcoid and Crohn's disease, in a steroid-resistant or steroid-sensitive patient. The method comprises administering to the patient an effective amount of a CD25 binding molecule and a steroid.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Hybridoma Cell Line G250 and its use for Producing Monoclonal Antibodies]]></title>
<link>http://www.freepatentsonline.com/y2009/0274620.html</link>
<description><![CDATA[This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[ANTIOXIDANT FOR USE IN COSMETIC, MEDICATED AND PHARMACEUTICAL PREPARATIONS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274677.html</link>
<description><![CDATA[The invention provides the use a 2,2-dimethyl chroman as a SOD mimetic in a cosmetic preparation. Cosmetic preparations comprising a 2,2-dimethyl chroman as a SOD mimetic are described, as well as methods for treating or preventing free radical damage to skin cells and treating or preventing hair loss which comprise topical administration of a 2,2-dimethyl chroman as a SOD mimetic.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[METHOD FOR OBTAINING HOLLOW PARTICLES]]></title>
<link>http://www.freepatentsonline.com/y2009/0274734.html</link>
<description><![CDATA[Described is a method for obtaining hollow particles, having a particle wall and a particle lumen, the particle having dimensions of between 1 nm and 100 μm, from a mixture comprising a liquid medium comprising at least one colloid or solute, the method comprising freezing said mixture and lyophilising the obtained frozen mixture, characterised in that a volume of at least 0.1 μl of the mixture is subjected to a freezing step comprising: (a) (1) quench freezing the mixture resulting in a quench frozen mixture, and (2) incubating said quench frozen mixture at a temperature above the quench freezing temperature and below the melting point of the liquid medium, orb) (1) reducing the temperature of the mixture at a rate of 1 to 100° C./minute to below the freezing temperature of the mixture and (2) incubating said frozen mixture at a temperature above the temperature of the mixture and below the melting point of the liquid medium. Further, hollow particles obtainable by the said method, compositions comprising said hollow particles and uses thereof are described.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals]]></title>
<link>http://www.freepatentsonline.com/y2009/0274755.html</link>
<description><![CDATA[The present invention is directed to a process for the catalytic oxidation of the thioether 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)methylthio)-1H-benzimidazole to its sulfoxide: 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl) methyl)methylsulfinyl)-1H-benzimidazole comprising: reacting the thioether with: 1) a transition metal catalyst; and, 2) an oxygen source; wherein the thioether is oxidized to a sulfoxide and wherein one of either the R and S enantiomers is formed to an enantiomeric excess.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Lipocalin-2 As A Prognostic and Diagnostic Marker For Heart And Stroke Risks]]></title>
<link>http://www.freepatentsonline.com/y2009/0274709.html</link>
<description><![CDATA[Methods and apparatus are disclosed for the measurement of lipocalin-2 in body fluids (including but not limited to blood, serum, plasma, urine, saliva, tear, etc.) by an assay such as an immunoassay or an immunotest for (1) the prediction of risk of future cardiovascular diseases; and (2) the determination of the likelihood that certain individuals will benefit to a greater or lesser extent from the use of certain treatments designed to prevent and/or treat cardiovascular diseases.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Genes and proteins, and their use]]></title>
<link>http://www.freepatentsonline.com/y2009/0274717.html</link>
<description><![CDATA[According to the present invention, a series of genes are identified in Group B  Streptococcus , the products of which may be associated with the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines to immunize a patient against microbial infection.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[SYNTHETIC GENE]]></title>
<link>http://www.freepatentsonline.com/y2009/0274726.html</link>
<description><![CDATA[The present invention relates to synthetic genes, processes for designing said synthetic genes and their uses in gene therapy and improved DNA vaccination. The novel synthetic genes and processes are codon shuffled so that they have reduced homology relative to a naturally occurring gene encoding the same protein without altering the overall codon usage frequency of the gene. In particular the present invention relates to improved polynucleotides and methods for the treatment or prevention of disease comprising codon-shuffled GM-CSF nucleic acid sequences. Nucleic acid vaccines of the present invention may comprise a combination of a nucleotide sequence encoding codon-shuffled GM-CSF, a nucleotide encoding an antigen against which it is desired to raise an immune response and a toll-like receptor (TLR) agonist.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Low viscosity, high molecular weight linear random-block silicone polyalkyleneoxide copolymers]]></title>
<link>http://www.freepatentsonline.com/y2009/0274643.html</link>
<description><![CDATA[The present invention describes novel non-hydrolyzable, linear, random block copolymers comprising units of polysiloxanes and polyalkyleneoxides linked by bis-aminofunctional groups. These copolymers have been successfully applied as textile enhancers as well as conditioning agents for hair and skin care products.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method of culturing vascular smooth muscle cells, culture device and medical material obtained by the culture]]></title>
<link>http://www.freepatentsonline.com/y2009/0274664.html</link>
<description><![CDATA[There is provided a method for culturing vascular smooth muscle cells while maintaining their normal function, and a culture device and regenerative medical material for the same. The method takes advantage of vascular smooth muscle cell recognition of elastin as an extracellular matrix. The invention provides a method for culturing vascular smooth muscle cells on elastin, a culture device having elastin anchored on the cell-growing surface, a culture device wherein the cell-growing surface is composed of an elastin molded article, and medical materials obtained by culturing vascular smooth muscle cells using such culture devices.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Stem Cells For Treating Lung Diseases]]></title>
<link>http://www.freepatentsonline.com/y2009/0274665.html</link>
<description><![CDATA[The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Combined Regulation of Neural Cell Production]]></title>
<link>http://www.freepatentsonline.com/y2009/0274668.html</link>
<description><![CDATA[This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A PDE-4 INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]></title>
<link>http://www.freepatentsonline.com/y2009/0274676.html</link>
<description><![CDATA[A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a phosphodiesterase-4 inhibitor for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Inhibition of urokinase-type plasminogen activator (uPA) activity]]></title>
<link>http://www.freepatentsonline.com/y2009/0274695.html</link>
<description><![CDATA[The invention concerns methods for inhibiting the binding of urokinase-type plasminogen activator (uPA) to its receptor uPAR and/or inhibiting uPA biological activity. The invention further concerns methods for inhibiting tumor formation or metastasis, angiogenesis, such as tumor angiogenesis, and screening assays for identifying CYTL1 agonists.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION]]></title>
<link>http://www.freepatentsonline.com/y2009/0274730.html</link>
<description><![CDATA[Provided are electrokinetically-generated fluids (e.g., gas-enriched electrokinetic fluids or solutions), and therapeutic compositions and methods for use in treating inflammation or at least one symptom of inflammation. The electrokinetically-generated fluids or therapeutic compositions and methods include electrokinetically-generated aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[HEPATITIS C VIRUS INHIBITORS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274648.html</link>
<description><![CDATA[Hepatitis C virus inhibitors having the general formula  
 are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274657.html</link>
<description><![CDATA[The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:  
 which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods of treating inflammation using IL-17 antagonists]]></title>
<link>http://www.freepatentsonline.com/y2009/0274703.html</link>
<description><![CDATA[Aspects of the present invention provide methods for treating diseases associated with IL-17 mediated inflammatory or immunoregulatory reactions.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[METHODS FOR TREATING INFLAMMATION]]></title>
<link>http://www.freepatentsonline.com/y2009/0274696.html</link>
<description><![CDATA[Provided are methods and compositions for reducing airway hyperresponsiveness and other inflammatory diseases, disorders and conditions in a mammal by decreasing FIZZ1 (Found in Inflammatory Zone 1) activity. Also provided are methods and compositions for identifying modulators of airway inflammation and/or inhibitors of FIZZ1. The present invention encompasses modulators of airway inflammation and/or inhibitors of FIZZ1 and uses thereof. In addition, the present invention provides methods and compositions for enhancing an immune response based on FIZZ1 protein.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274710.html</link>
<description><![CDATA[Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[LEVELS OF BLyS/APRIL HETEROTRIMERS IN SERUM AND USE IN DIAGNOSTIC METHODS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274711.html</link>
<description><![CDATA[The present invention provides a method of measuring the levels of BLyS/APRIL heterotrimers (HT) in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with HT antagonists, either singly or in combination with other immune suppressive drugs.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[CHIMERIC PROTEINS THAT INDUCE EFFECTS DIRECTED AGAINST VIRUSES]]></title>
<link>http://www.freepatentsonline.com/y2009/0274718.html</link>
<description><![CDATA[The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from  Neisseria meningitidis  with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Anti-dementia substance from hericium erinaceum and method of extraction]]></title>
<link>http://www.freepatentsonline.com/y2009/0274720.html</link>
<description><![CDATA[A fat-soluble fraction extracted from the fruiting body of  Hericium erinaceum  is demonstrated to inhibit the neuronal toxicity of amyloid beta-peptide (Aβ) and induce the synthesis of nerve growth factor (NGF), and has great potential as an active ingredient for pharmaceutical products, health food products, food products and/or beverages to prevent and/or treat dementia, especially Alzheimer-type dementia. This invention is to provide the bioactive fraction and its preparation method.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Modified vaccinia ankara virus vaccine]]></title>
<link>http://www.freepatentsonline.com/y2009/0274723.html</link>
<description><![CDATA[The present invention relates, in general, to vaccines and, in particular, to a modified vaccinia Ankara (MVA) virus, to a composition comprising such a virus and to methods of using same to induce an immune response.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[NOVEL RECOMBINANT AND MUTANT ADENOVIRUSES]]></title>
<link>http://www.freepatentsonline.com/y2009/0274724.html</link>
<description><![CDATA[The present invention provides novel viral vectors. In one embodiment, the present invention provides mutant and recombinant bovine adenoviruses having a deletion and/or insertion of DNA in the early gene region 4 (E4). In another embodiment, the present invention provides mutant and recombinant bovine adenovirus 1 viruses having a deletion and/or insertion of DNA in the early gene region 3 (E3). The present invention also contemplates the use of the viral vectors for vaccination, gene therapy or other applications as suitable.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[PRODUCTION OF ENVELOPED PHARMACEUTICAL DOSAGE FORMS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274731.html</link>
<description><![CDATA[A process for at least partially enveloping a pharmaceutical dosage form, in which the dosage form is surrounded by a shrinkable film, and the film is subsequently shrunk is described.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Pharmaceutical preparation containing copolyvidone]]></title>
<link>http://www.freepatentsonline.com/y2009/0274733.html</link>
<description><![CDATA[A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[POLYMERS CONTAINING POLY(ESTER AMIDES) AND AGENTS FOR USE WITH MEDICAL ARTICLES AND METHODS OF FABRICATING THE SAME]]></title>
<link>http://www.freepatentsonline.com/y2009/0274741.html</link>
<description><![CDATA[Polymers containing poly(ester amides) and agents for use with medical articles and methods of fabricating the same are disclosed. The medical article generally comprises an implantable substrate having a coating, and the coating contains a polymer comprising a polymeric product of a reaction comprising a polyol, a polycarboxylic acid, an amino acid and an agent.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compositions and Methods for Drug Delivery]]></title>
<link>http://www.freepatentsonline.com/y2009/0274765.html</link>
<description><![CDATA[The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises an opsonin, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[FRAKTIONEN AUS MOLKEPERMEAT UND DEREN VERWENDUNG ZUR PRAVENTION UND THERAPIE DES TYP-2 DIABETES UND DES METABOLISCHEN SYNDROMS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274768.html</link>
<description><![CDATA[Fractions of whey permeate, preferably made, of sweet whey permeate and more preferably of hydrolyzed or partially hydrolyze sweet whey permeate are provided, particularly for use in the production of pharmaceutical compositions, or of food, for the treatment, prophylaxis, or alleviation of glucose intolerance and insulin resistance, and thus of symptoms of the metabolic syndrome, type 2 diabetes, and complications in humans.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[CELLULAR EXTRACTS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274770.html</link>
<description><![CDATA[The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. This invention relates to the use of cells and cellular extracts in rejuvenation and healing technologies thereby improving healing and regeneration of all bodily tissues and organs. The present invention relates to compositions and methods of managing, preventing, and treating scars. The invention also relates to prevention of deterioration, damage and malfunction of cells and tissues, and to promote, improve or exceed cellular function in order to promote, improve and exceed appearance, vitality and health. In some embodiments, the invention relates to compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[ANTIPROLIFERATIVE COMBINATION COMPRISING CYC-682 AND A CYTOTOXIC AGENT]]></title>
<link>http://www.freepatentsonline.com/y2009/0274773.html</link>
<description><![CDATA[A first aspect of the invention relates to a combination comprising 2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabi-nofuranosyl-cytosine, or a metabolite thereof, or a pharmaceutically acceptable salt thereof, and a cytotoxic agent selected from (a) a vinca alkaloid; (b) a taxane; (c) a cytosine analogue; (d) an anthracycline; and (e) a platinum antineoplastic agent. A second aspect of the invention relates to a pharmaceutical product comprising the above combination as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method for treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering the above combination.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method for the Diagnosis and Treatment of Conditions Involving Aberrant Erythrocyte Potassium Levels]]></title>
<link>http://www.freepatentsonline.com/y2009/0274776.html</link>
<description><![CDATA[The present invention provides a systematic approach that allows health care providers (e.g., physicians) to use erythrocyte potassium measurements as an indicator of hypertension or risk of developing hypertension. In particular, the present invention provides systems and methods for treating conditions involving aberrant erythrocyte potassium levels (e.g., hypertension), preventing the onset of conditions involving aberrant erythrocyte potassium levels, identifying individuals at risk for developing hypertension, and evaluating the effectiveness of treatments for conditions involving aberrant erythrocyte potassium levels (e.g., hypertension).]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compositions Exhibiting Inhibition Of Cyclooxygenase-2]]></title>
<link>http://www.freepatentsonline.com/y2009/0274778.html</link>
<description><![CDATA[The invention provides a method of treating diabetes by administering to an individual having diabetes a composition containing a hops extract. In a particular embodiment, an individual having diabetes can be administered a composition comprising a first component selected from the group consisting of alpha acids and beta acids, essential oils, fats and waxed, with the proviso that the first component and second component are not the same compound. The invention additional provides a method of treating diabetes by administering to an individual having diabetes a composition comprising a first component selected from a curcuminoid and a second component selected from an alpha acid and a beta acid.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[EXTRACTS AND COMPOUNDS FROM "TULBAGHIA VIOLACEA" AND THEIR USE AS BIOLOGICAL PLANT PROTECTING AGENTS]]></title>
<link>http://www.freepatentsonline.com/y2009/0275472.html</link>
<description><![CDATA[The invention provides extracts and preparations based on the species  Tulbaghia violacea  (Harv.) (wild garlic), which elicits a significant antimicrobial, preferably antifungal activity in vitro and in vivo, even under field and glasshouse conditions. Moreover, these extracts deriving from the soil parts as well as of the aerial parts of the plant elicit a significant bio-stimulatory activity, expressed, above all, by an increased growth metabolism supporting seed growth. Furthermore, combined extracts or preparations from  Tulbaghia violacea  and species of the genus  Agapanthus  show a higher antifungal and bio-stimulatory efficacy as compared to the extracts or preparations of the single species, indicating that synergism is participated in the involved biological processes.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[RADIOTRACERS FOR IMAGING P-GLYCOPROTEIN FUNCTION]]></title>
<link>http://www.freepatentsonline.com/y2009/0274624.html</link>
<description><![CDATA[P-glycoprotein transporter (P-gp) acts as a pump at the blood-brain barrier to exclude a wide range of xenobiotics (e.g., toxins, drugs, etc.) from the brain and is also expressed in a tumor in response to exposure to established or prospective chemotherapeutics (a phenomenon known as multidrug resistance). This invention concerns the preparation and use of radiotracers for imaging P-gp function in vitro and in vivo. Radiotracers of the present invention are avid substrates for P-gp and have structures based on N-Desmethyl-loperamide.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Depigmenting or Brigthening Cosmetic Composition at Least One Oxazolin as an Active Ingredient]]></title>
<link>http://www.freepatentsonline.com/y2009/0274637.html</link>
<description><![CDATA[The invention relates to the cosmetic use of at least one oxazolin as a depigmenting active ingredient in a depigmenting composition, and to the associated cosmetic treatment method. The invention also relates to the use of at least one oxazolin for preparing an active medicament as a depigmenting agent, and to a depigmenting cosmetic composition comprising at least one oxazolin as a depigmenting active ingredient.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[ELECTRONIC CAPSULE FOR TREATING GASTROINTESTINAL DISEASE]]></title>
<link>http://www.freepatentsonline.com/y2009/0275923.html</link>
<description><![CDATA[The present invention discloses an ingestible capsule containing drug and a method for controlled administration of the drug in a mammal for treatment of a disease of the GI tract. The capsule has electronic control means for dispensing the drug substantially to the diseased tissue sites of the GI tract, according to a pre-determined drug release profile obtained prior to administration from the specific mammal.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274654.html</link>
<description><![CDATA[The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[USE OF BIFIDOBACTERIUM LONGUM FOR THE PREVENTION AND TREATMENT OF INFLAMMATION]]></title>
<link>http://www.freepatentsonline.com/y2009/0274661.html</link>
<description><![CDATA[The invention relates to the use, in the manufacture of a medicament or a therapeutic nutritional composition for preventing or reducing inflammation in a mammal, of  bifidobacterium longum  ATCC BAA-999.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[RESORBABLE CERAMICS WITH CONTROLLED STRENGTH LOSS RATES]]></title>
<link>http://www.freepatentsonline.com/y2009/0276056.html</link>
<description><![CDATA[Particular aspects provide bioresorbable and biocompatible compositions for bioengineering, restoring or regenerating tissue or bone, comprising a three-dimensional porous or non-porous scaffold material comprising a calcium phosphate-based ceramic having at least one dopant therein selected from metal ion or ion dopants and metal oxide dopants, wherein the composition is sufficiently biocompatible to provide for a cell or tissue scaffold, and resorbable at a controlled resorption rate for controlled stregthloss, depending on dopant composition, under body, body fluid or simulated body fluid conditions. Preferably, the at least one dopant is selected from the group consisting of Zn 2+ , Mg 2+ , Si 2+ , Na + , K + , Sr 2+ , Cu 2+ , Fe 3+ /Fe 2+ , Ag + , Ti 4+ , CO 3 2− , F − , MgO, ZnO, NaF, KF, FeO/Fe 2 O 3 , SrO, CuO, SiO 2 , TiO 2 , Ag 2 O and CaCO 3 , present in an amount between 0 and about 10 w %, from about 0.5 to about 5 w %, or from about 1 to about 3 w %, and methods of using same.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Dendritic Cells Transiently Transfected with a Membrane Homing Polypeptide and their use]]></title>
<link>http://www.freepatentsonline.com/y2009/0274669.html</link>
<description><![CDATA[The invention provides improved methods of producing dendritic cells (“DCs”) that transiently express a membrane homing peptide and optionally at least one additional antigen. These DCs have the ability to home to lymph nodes in vivo. In some embodiments, these DCs can be administered to a patient intravenously and can subsequently home to lymph nodes and stimulate an immune response. The methods and DCs of the invention are useful for the treatment of various diseases and disorders.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Heterocyclic Oxime Compounds, Process for Their Preparation and Pharmaceutical Compositions Containing Them]]></title>
<link>http://www.freepatentsonline.com/y2009/0274674.html</link>
<description><![CDATA[Compounds of formula (I):  
 wherein:
 
     X represents a hydrogen or halogen atom or an alkyl group, R 1 , R 2 , R 3  and R 4  are as defined in the description, A represents an alkylene chain as defined in the description, B represents an alkyl or alkenyl group substituted by a group 
     
 
 
     D represents a pyridine nucleus.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR]]></title>
<link>http://www.freepatentsonline.com/y2009/0274706.html</link>
<description><![CDATA[The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Mutant Viruses]]></title>
<link>http://www.freepatentsonline.com/y2009/0274728.html</link>
<description><![CDATA[An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[MULTIMODAL HIGH STRENGTH DEVICES AND COMPOSITES]]></title>
<link>http://www.freepatentsonline.com/y2009/0274742.html</link>
<description><![CDATA[An oriented implantable biodegradable multimodal device is disclosed. The orientated implantable biodegradable multimodal device includes a blend of a first polymer component having a first molecular weight (mwt) together with at least a second polymer component having a mwt which is less than that of the first component. The polymer within the blend may be in a uniaxial, biaxial or triaxial orientation. Also disclosed is a composite thereof with matrix polymer, processes for the preparation thereof and the use thereof as an implantable biodegradable device such as a high strength trauma fixation device suitable for implantation into the human or animal body. As examples the high strength trauma device may take the form of plates, screws, pins, rods, anchors or scaffolds.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[PHARMACEUTICAL POLISH FORMULATIONS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274757.html</link>
<description><![CDATA[Polish compositions for coating pharmaceutical solid dosage forms such as tablets are disclosed. The polish composition comprises water, coating agent, and a film forming agent. Polished pharmaceutical solid dosage forms such as tablets comprising a polished exterior surface are also disclosed. Processes of polishing pharmaceutical solid dosage forms such as tablets are disclosed.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Immunotherapeutic Formulations with Interleukin-2-Neutralizing Capacity]]></title>
<link>http://www.freepatentsonline.com/y2009/0274647.html</link>
<description><![CDATA[The present invention is related to pharmaceutical compositions based on vaccines and monoclonal antibodies that neutralize the Interleukin-2, which are useful in the treatment of tumors.  Particularly the present invention is related to therapeutic formulations able to increase the immunogenicity of the IL-2 conjugated to the carrier protein P64k from the  neisseria meningitidis  in montanide ISA 51 adjuvant for the induction of IL-2 neutralizing autoantibodies and the effective methods for the treatment of tumors, including breast cancer and melanoma. Furthermore, the present invention is related to therapeutic combination of the IL-2 based vaccine with other cancer vaccines based on specific tumor antigens or tumor growth factors, as well as chemotherapeutics agents or radiotherapy of standard use for cancer treatment.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Tight Junction Modulating Peptides for Enhanced Mucosal Delivery of Therapeutic Compounds]]></title>
<link>http://www.freepatentsonline.com/y2009/0274658.html</link>
<description><![CDATA[Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject, in which the permeabilizing peptide is a tight junction modulating peptide (TJMP), a TJMP analogue, a conjugate of a TJMP, a conjugate of a TJMP analogue, or complexes thereof. The permeabilizing agent reversibly enhances mucosal epithelial paracellular transport, typically by modulating epithelial junctional structure and/or physiology at a mucosal epithelial surface in the subject.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[NUCLEOSIDE PHOSPHONATE DERIVATIVES]]></title>
<link>http://www.freepatentsonline.com/y2009/0274686.html</link>
<description><![CDATA[The present invention discloses compounds of formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof:  
 which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method of Treating Cancer using a cMet and AXL Inhibitor and an ErbB Inhibitor]]></title>
<link>http://www.freepatentsonline.com/y2009/0274693.html</link>
<description><![CDATA[The present invention relates to a method of treating cancer in a patient comprising administering to the patient therapeutically effective amounts of:  a) a compound of formula A: 
 or a pharmaceutically acceptable salt thereof, wherein R 1 -R 4 , p, and q are as defined; and (b) an erbB inhibitor that inhibits erbB-1 or erbB-2 or erbB-3 receptor or a combination thereof. The method of the present invention addresses a need in the art with the discovery of a combination therapy that shows evidence of being a more effective therapy than previously disclosed therapies.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Combination anti-cancer therapy]]></title>
<link>http://www.freepatentsonline.com/y2009/0274698.html</link>
<description><![CDATA[The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. Examples of such anti-cancer agents or treatments include doxorubicin, cisplatin, or ionizing radiation. The present invention also provides a pharmaceutical composition comprising an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of the anti-cancer agent melphalan or 5-FU, and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[METHODS AND COMPOSITIONS FOR CONTROLLED DELIVERY OF PHYTOCHEMICAL AGENTS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274746.html</link>
<description><![CDATA[The presently-disclosed subject matter provides compositions and methods for treating a cancer by providing a composition comprising a biocompatible polymeric matrix incorporating an effective amount of a phytochemical agent, a combination of phytochemical agents, or a phytochemical agent and a chemotherapeutic agent. Further, provided is a device for uterine cervical insertion for local delivery.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[TUMOR VASCULATURE MARKERS AND METHODS OF USE THEROF]]></title>
<link>http://www.freepatentsonline.com/y2009/0274619.html</link>
<description><![CDATA[This invention provides methods of detecting and localizing tumor vasculature cells (TVC) and solid tumors; and treating, impeding vascularization of, and determining the stage of solid tumors in a subject, comprising the step of contacting a subject or a TVC with a ligand that binds to a nucleic acid molecule of the present invention, or binds to a protein encoded by the nucleic acid molecule.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[RED BLOOD CELL-DERIVED VESICLES AS A NANOPARTICLE DRUG DELIVERY SYSTEM]]></title>
<link>http://www.freepatentsonline.com/y2009/0274630.html</link>
<description><![CDATA[Red blood cell-derived vesicles (RDV) as a nanoparticle drug delivery system. The RDV are smaller than one micrometer, capable of encapsulating and delivering an exogenous substance into cells. The substance may be at least one selected from the group consisting of fluorophores, nucleic acids, superparamagnetic compounds and therapeutic agents. The RDV are capable of delivering encapsulated substances into cells including stem cells. The delivered substance within the cell or stem cell may be traced or tracked using a suitable device either in vitro or in vivo.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[HEPATITIS C VIRUS INHIBITORS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274656.html</link>
<description><![CDATA[Hepatitis C virus inhibitors are disclosed having the general formula:  
 
     wherein R 1 , R 2 , R 3 , R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Recombinant Toxin Fragments]]></title>
<link>http://www.freepatentsonline.com/y2009/0274708.html</link>
<description><![CDATA[Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plasma membrane associated proteins essential to exocytosis; and said second domain is a clostridial neurotoxin heavy chain H N  portion or a fragment or a variant thereof, wherein said second domain is capable of (i) translocating the polypeptide into a cell or (ii) increasing the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both translocating the polypeptide into a cell and increasing the solubility of the polypeptide compared to the solubility of the first domain on its own; and wherein the second domain lacks a functional C-terminal part of a clostridial neurotoxin heavy chain designated H C  thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell surface receptors to which native clostridial neurotoxin binds. Antibodies that bind to the polypeptides, and compositions comprising these antibodies, are also provided, as are DNA vaccines comprising polynucleotides that encode these polypeptides.  The antigenic and antibody compositions, and the DNA vaccine compositions, can be used in methods of immunising against, or treating, clostridial neurotoxin poisoning in a subject by administering to that subject a therapeutically effective amount of the composition.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[TUMOUR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR II MOLECULES AND RELATED ANTI-CANCER VACCINE]]></title>
<link>http://www.freepatentsonline.com/y2009/0274714.html</link>
<description><![CDATA[The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class II molecules of human tumour cell lines, which can be used in vaccine compositions for eliciting anti-tumour immune responses.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Recombinant RSV Virus Expression Systems And Vaccines]]></title>
<link>http://www.freepatentsonline.com/y2009/0274727.html</link>
<description><![CDATA[The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[MEDIA FOR CLOSTRIDIUM BACTERIUM AND PROCESSES FOR OBTAINING A CLOSTRIDIAL TOXIN]]></title>
<link>http://www.freepatentsonline.com/y2009/0274729.html</link>
<description><![CDATA[Animal product free (APF) media and processes for the culture and fermentation of botulinum toxin producing  Clostridium botulinum  bacteria. The botulinum toxin obtained can be used for formulating and compounding botulinum toxin pharmaceutical compositions. The APF media can contain significantly reduced levels of meat or dairy by-products and use non-animal based products instead of the animal-derived products. Preferably, the APF media used are substantially free or free of animal derived products.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[MEDICAL DEVICES HAVING A BIORESORBABLE COATING LAYER WITH A PRE-DETERMINED PATTERN FOR FRAGMENTATION]]></title>
<link>http://www.freepatentsonline.com/y2009/0274743.html</link>
<description><![CDATA[Intravascular medical devices comprising a coating layer disposed on a substrate associated with the medical device, wherein the coating layer has a pre-determined fragmentation pattern. At least a portion of the coating layer comprises a plurality of discontinuous bioresorbable members, wherein the discontinuous bioresorbable members have a size less than the luminal diameter of an arteriole. The coating layer may be formed by excavating portions of a coating layer (e.g., by laser ablation) to create gaps which define the discontinuous bioresorbable members. In certain embodiments, the coating layer is formed of a heat-bondable material. In such embodiments, the discontinuous bioresorbable members may be adhered to the substrate via heat bonds. Also disclosed are methods of forming a coating layer on medical devices and methods of treating intravascular sites.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[TARGETING TNF-alpha CONVERTING ENZYME(TACE)- DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY]]></title>
<link>http://www.freepatentsonline.com/y2009/0274626.html</link>
<description><![CDATA[The invention provides methods for modulating tumor cell proliferation by contacting cells (e.g. tumor cells) with a TACE inhibitor and a compound that inhibits EGFR tyrosine kinase, whereby the TACE inhibitor enhances the sensitivity of the cell to the EGFR tyrosine kinase inhibitor. Additionally, methods for treating cancer and methods for identifying TACE inhibitors is also provided.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Therapeutic agent for infections, and treatment method using the same]]></title>
<link>http://www.freepatentsonline.com/y2009/0274651.html</link>
<description><![CDATA[(Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.
 
(Means for Solving Problems)
  The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[RETINAL PIGMENT EPITHELIAL STEM CELLS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274667.html</link>
<description><![CDATA[The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Lactobacillus Isolates Having Anti-Inflammatory Activities and Uses of the Same]]></title>
<link>http://www.freepatentsonline.com/y2009/0274672.html</link>
<description><![CDATA[Disclosed herein are two  Lactobacillus  isolates having anti-inflammatory activities and beneficial probiotic properties, i.e.,  Lactobacillus sakei  GMNL-76 and  Lactobacillus reuteri  GMNL-89, which were deposited in the Biosource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) under accession numbers BCRC 910355 and BCRC 910340 and in the China Center for Type Culture Collection (CCTCC) under accession numbers CCTCC M 207153 and CCTCC M 207154, respectively. The two  Lactobacillus  isolates and their sub-cultured offspring can be used in the preparation of a variety of food products, and in the manufacture of pharmaceutical compositions for treating and/or alleviating diseases associated with inflammation, such as rheumatoid arthritis.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[PRODUCTION AND USE OF HUMAN BUTYRYLCHOLINESTERASE]]></title>
<link>http://www.freepatentsonline.com/y2009/0274679.html</link>
<description><![CDATA[The present invention concerns the production of human butyrylcholinesterase (BuChE) in transgenic plants and use of the derived BuChE as effective countermeasures against toxic agents such as pesticides, toxins, certain drugs and non-conventional warfare agents, as well as treatments for diseases and conditions associated with depressed cholinesterase levels.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[UL16 BINDING PROTEIN 4]]></title>
<link>http://www.freepatentsonline.com/y2009/0274699.html</link>
<description><![CDATA[ULBP4, a novel member of the ULBP family has been isolated and characterized. ULBP4 is a useful activator of immune effector cells, particularly of NK cells.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[CHLAMYDIA PNEUMONIAE POLYNUCLEOTIDES AND USES THEREOF]]></title>
<link>http://www.freepatentsonline.com/y2009/0274701.html</link>
<description><![CDATA[The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of  Chlamydia pneumoniae , such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the  Chlamydia pneumoniae  genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing  Chlamydia pneumoniae  infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides. The invention finally comprises, pharmaceutical, in particular vaccine, compositions for the prevention and/or treatment of bacterial, in particular  Chlamydia pneumoniae , infections.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods and Compositions Comprising Anti-Idiotypic Antibodies to Anti-MMP-14 Antibodies]]></title>
<link>http://www.freepatentsonline.com/y2009/0275124.html</link>
<description><![CDATA[Provided are anti-idiotypic antibodies specific for a CDR of an anti-MMP-14 antibody for use as reagents in novel assays for anti-MMP-14 antibodies, pharmaceutical compositions and vaccines.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[IMPLANT COMPRISING A SURFACE OF REDUCED THROMBOGENICITY]]></title>
<link>http://www.freepatentsonline.com/y2009/0274737.html</link>
<description><![CDATA[An implant for a human or animal body, comprising a surface having reduced thrombogenic properties, whose surface has a wetting angle of Θ, where Θ≦80°. Also disclosed is a method for producing an implant and the use an implant to reduce the dose or concentration in administration of a concomitant systemic medication with one or more anticoagulant active ingredients before, during or after implantation of the implant in a human or animal body.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[COSMETIC AND DERMATOLOGICAL FORMULATIONS OF MNTF PEPTIDES]]></title>
<link>http://www.freepatentsonline.com/y2009/0274752.html</link>
<description><![CDATA[The disclosure is directed to methods and compositions that include MNTF peptides and their analogs for cosmetic and dermatological purposes.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274694.html</link>
<description><![CDATA[Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[TADG-15: an extracellular serine protease overexpressed in carcinomas]]></title>
<link>http://www.freepatentsonline.com/y2009/0274618.html</link>
<description><![CDATA[The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Hepatitis C Virus Inhibitors]]></title>
<link>http://www.freepatentsonline.com/y2009/0274652.html</link>
<description><![CDATA[Hepatitis C virus inhibitors having the general formula  
 are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Antibodies to OPGL]]></title>
<link>http://www.freepatentsonline.com/y2009/0274688.html</link>
<description><![CDATA[Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[CROSS-LINKERS AND THEIR USES]]></title>
<link>http://www.freepatentsonline.com/y2009/0274713.html</link>
<description><![CDATA[Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Flaky Particles and Luster Pigment, and Cosmetic, Coating Composition, Resin Composition and Ink Composition Each Containing the Same]]></title>
<link>http://www.freepatentsonline.com/y2009/0274735.html</link>
<description><![CDATA[Flaky particles of the present invention have a particle size distribution in which a value of D90/D10 is at least 2.0 but not more than 3.0, a value of D10 is at least 4.7 μm but not more than 25 μm, and a maximum particle diameter is 90 μm or less, where D10 is defined as a particle diameter at which a cumulative volume of particles reaches 10% when counted from the smaller side, and D90 is defined as a particle diameter at which a cumulative volume of particles reaches 90% when counted from the smaller side. A luster pigment of the present invention contains flaky particles and at least one selected from a metallic layer and a metallic oxide layer that are formed on at least a part of the surface of each of the flaky particles. The luster pigment has a particle size distribution in which a value of D90/D10 is at least 2.0 but not more than 3.0, a value of D10 is at least 4.7 μm but not more than 25 μm, and a maximum particle diameter is 90 μm or less, where D10 is defined as a particle diameter at which a cumulative volume of particles reaches 10% when counted from the smaller side, and D90 is defined as a particle diameter at which a cumulative volume of particles reaches 90% when counted from the smaller side.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[REHYDRATABLE PHARMACEUTICAL PRODUCT]]></title>
<link>http://www.freepatentsonline.com/y2009/0274762.html</link>
<description><![CDATA[A pharmaceutical product comprising lyophilised polymer matrix including a biologically active compound, of particular utility for embolisation, having improved rehydration properties is packaged in an airtight package under vacuum.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compositions and Methods for The Treatment of Cancer]]></title>
<link>http://www.freepatentsonline.com/y2009/0274625.html</link>
<description><![CDATA[The instant invention provides methods and compositions for the treatment and diagnosis of cancer, e.g., cancers characterized by the expression of prostate specific membrane antigen (PSMA).]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Materials and Methods Relating to Cell Based Therapies]]></title>
<link>http://www.freepatentsonline.com/y2009/0274663.html</link>
<description><![CDATA[The invention provides a novel multipotent cell population of adult origin that can be used to treat ageing and disease, particularly by transplantation to site of cellular damage.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[VECTOR ENCODING HUMAN GLOBIN GENE AND USE THEREOF IN TREATMENT OF HEMOGLOBINOPATHIES]]></title>
<link>http://www.freepatentsonline.com/y2009/0274671.html</link>
<description><![CDATA[Recombinant lentiviral vectors having a region encoding a functional β-globin gene; and large portions of the β-globin locus control regions which include DNase I hypersensitive sites HS2, HS3 and HS4 provides expression of β-globin when introduced into a mammal, for example a human, in vivo. Optionally, the vector further includes a region encoding a dihydrofolate reductase. The vector may be used in treatment of hemoglobinopathies, including β-thalessemia and sickle-cell disease. For example, hematopoietic progenitor or stem cells may be transformed ex vivo and then restored to the patient. Selection processes may be used to increase the percentage of transformed cells in the returned population. For example, a selection marker which makes transformed cells more drug resistant than untransformed cells allows selection by treatment of the cells with the corresponding drug.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Human Phospholipases]]></title>
<link>http://www.freepatentsonline.com/y2009/0274680.html</link>
<description><![CDATA[The invention provides human lipid metabolism enzymes (LME) and polynucleotides which identify and encode LME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of LME.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[DEMETHYLATION AND INACTIVATION OF PROTEIN PHOSPHATASE 2A]]></title>
<link>http://www.freepatentsonline.com/y2009/0274682.html</link>
<description><![CDATA[Embodiments of the present invention relate to atomic coordinates for PME-1 alone or in complex with PP2A, as well as methods for using these atomic coordinates to prepare inhibitors of PME-1 and/or PP2A and inhibitors prepared using such methods. Further embodiments relate to biochemical analyses of the interactions of PME-1 alone or in complex with PP2A. Further embodiments relate to compositions including mimetics and small molecules, optionally, secondary agents, which may be used to treat disorders in which PME-1 and/or PP2A activity plays a contributing role.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods for the Identification of Modulators of OSGPR114 or OSGPR78 Activity, and their use in the Treatment of Disease]]></title>
<link>http://www.freepatentsonline.com/y2009/0274684.html</link>
<description><![CDATA[This invention relates to the identification of LPA as a ligand for the G-protein coupled receptors OSGPR 114 and OSGPR78. The invention is directed to new methods for screening candidate drugs for their ability to modulate the activity of OSGPR114 or OSGPR78, and new pharmaceutical agents identified by these methods. It is also directed to the use of such agents in the manufacture of medicaments for the treatment of OSGPR114 or OSGPR78 mediated diseases, and methods of treating diseases such as cancers by administering to an individual a therapeutic amount of a modulator of OSGPR114 or OSGPR78 identified by these methods.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[ATTENUATION OF HYPOXIA INDUCED CARDIOVASCULAR DISORDERS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274687.html</link>
<description><![CDATA[Blockade of stromal derived factor-1 (SDF-1), a stem cell mobilizer and/or its receptor, chemokine receptor 4 (CXCR4) attenuates and reverses hypoxia-induced cardiopulmonary remodeling in vivo. Compositions for treating hypoxia-induced cardiovascular disorders modulate the SDF-1/CXCR4 axis.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF]]></title>
<link>http://www.freepatentsonline.com/y2009/0274692.html</link>
<description><![CDATA[The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method of treatment and Agents useful for same]]></title>
<link>http://www.freepatentsonline.com/y2009/0274702.html</link>
<description><![CDATA[The present invention relates generally to a method for the treatment and prophylaxis of inflammatory conditions. The present invention is predicated in part on the identification of cells of the monocyte/macrophage lineage being critical for inflammation and, in particular, chronic inflammation. In accordance with the present invention, it is proposed that the reduction in levels of monocyte/macrophage-type cells and/or a reduction in the production of inflammatory and pro-inflammatory mediators by these cells, especially locally, is effective in reducing inflammatory conditions. The present invention further provides animal models useful for screening for reducing levels of monocyte/macrophage-type cells and/or reducing the production of inflammatory and pro-inflammatory mediators of these cells.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[DPH2 GENE DELETION MUTANT AND USES THEREOF]]></title>
<link>http://www.freepatentsonline.com/y2009/0274670.html</link>
<description><![CDATA[Diphtheria and  Pseudomonas  infections are very common worldwide. The toxins involved in the pathogenesis of those diseases act by inactivating the elongation factor-2 (EF-2), therefore blocking protein synthesis and leading to cell death. Diphthamide formation on EF-2 is a prerequisite step in the inactivation of EF-2, and Dph proteins have been identified as modulating this process. The present application concerns Dph2 deletion mutant genes and proteins and their uses in vitro and in vivo.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[NOVEL GENE ENCODING A DNA REPAIR ENZYME AND METHODS OF USE THEREOF]]></title>
<link>http://www.freepatentsonline.com/y2009/0274681.html</link>
<description><![CDATA[An isolated nucleic acid molecule encoding a human DNA repair enzyme, MED1, is disclosed. Like other mismatch repair genes which are mutated in certain cancers, MED1, encoding nucleic acids, proteins and antibodies thereto may be used to advantage in genetic or cancer screening assays. MED1, which recognizes and cleaves DNA, may also be used for the diagnostic detection of mutations and genetic variants.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[IL-31 RECEPTOR ANTIBODIES]]></title>
<link>http://www.freepatentsonline.com/y2009/0274700.html</link>
<description><![CDATA[Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[IL-13 BINDING AGENTS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274705.html</link>
<description><![CDATA[Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Novel crosslinked polymeric substrates methods of preparation and end use applications of the substrates]]></title>
<link>http://www.freepatentsonline.com/y2009/0274634.html</link>
<description><![CDATA[A composition of matter wherein the composition comprises a siliceous substrate having silanols on the surface and a polymer selected from the group consisting essentially of a water soluble polymer, a water soluble copolymer, an alcohol soluble polymer, an alcohol soluble copolymer, and combinations of such polymers, wherein the polymer is chemically bonded to the siliceous substrate by a silane linking material having the general formula  
 
<?in-line-formulae description="In-line Formulae" end="lead"?>O 3/2 SiQY<?in-line-formulae description="In-line Formulae" end="tail"?>
 that is derived from an alkoxy-functional silane having the general formula 
 
<?in-line-formulae description="In-line Formulae" end="lead"?>(RO) 3 SiQX<?in-line-formulae description="In-line Formulae" end="tail"?>
 and processes for preparing the crosslinked polymer that is chemically bonded to the surface of the siliceous substrate.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[INHIBITORS OF ASPARTYL PROTEASE]]></title>
<link>http://www.freepatentsonline.com/y2009/0274650.html</link>
<description><![CDATA[The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Anti-IL-12 Antibodies, Nucleic Acids Encoding Antibodies, and Methods of Production]]></title>
<link>http://www.freepatentsonline.com/y2009/0274707.html</link>
<description><![CDATA[Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[CHLAMYDIA TRACHOMATIS GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF INFECTION]]></title>
<link>http://www.freepatentsonline.com/y2009/0274719.html</link>
<description><![CDATA[The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of  Chlamydia trachomatis , such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the  Chlamydia trachomatis  genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing  Chlamydia trachomatis  infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides. The invention finally comprises, pharmaceutical, in particular vaccine, compositions for the prevention and/or treatment of bacterial, in particular  Chlamydia trachomatis , infections.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE]]></title>
<link>http://www.freepatentsonline.com/y2009/0274666.html</link>
<description><![CDATA[The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors Also included are methods of making and using these co-stimulatory polypeptides.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof]]></title>
<link>http://www.freepatentsonline.com/y2009/0274632.html</link>
<description><![CDATA[The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof as bitter taste blockers or flavor modulators in, e.g., coffee and coffee flavored foods, beverages and medicaments. Also, the present invention relates to the discovery of a compound that antagonizes numerous different human T2Rs and the use thereof in assays and as a bitter taste blocker in compositions for ingestion by humans and animals.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS]]></title>
<link>http://www.freepatentsonline.com/y2009/0274655.html</link>
<description><![CDATA[Anti-viral agents of compounds of Formula (I): wherein A, R 1 , R 2  and R 3  are as defined in the specification, processes for their preparation and their use in HCV treatment are provided.]]></description>
<pubDate>Thu, 05 Nov 2009 08:00:00 EST</pubDate>
</item>

</channel>
</rss>
